Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Total Current Liabilities
All obligations due within one year.
Actuate Therapeutics IncNASDAQ: ACTU
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 48.4% from a year ago
Total current liabilities stood at $4.72M at the end of Q1 FY2026, down 48.4% from a year earlier and down 17.3% from the prior quarter. Over 3 fiscal years it compounded at +9.5% a year.
Context
- Total current liabilities amounted to 53.0% of total assets at the end of Q1 FY2026, down 151.2 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -48.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 5.71M USD
- Year-over-year change
- -35.2%
- 3-year CAGR
- +9.5%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.71M | -35.2% |
| FY2024 | 2024-12-31 | 8.8M | +27.2% |
| FY2023 | 2023-12-31 | 6.92M | +59.3% |
| FY2022 | 2022-12-31 | 4.34M | — |
Total Current Liabilities vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -48.4% is the 6th highest of 9, against a peer median of -37.5%.
- Total current liabilities amounts to 53.0% of total assets for ACTU, versus a peer median of 9.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $40.97M USD | -62.7% | -9.5% | 17.1% | |
| Mar 2026 | $19.34M USD | -38.2% | -39.1% | 16.4% | |
| Mar 2026 | $18.21M USD | -2.9% | +0.3% | 4.9% | |
| Mar 2026 | $16.08M USD | -3.9% | +24.3% | 3.2% | |
| Mar 2026 | $8.96M USD | -56.1% | -12.4% | 5.7% | |
| Mar 2026 | CHF 8.77M CHF | -2.1% | -13.9% | 10.0% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $7.23M USD | -36.7% | +5.7% | 31.9% |
| Mar 2026 | $5.49M USD | -81.2% | -25.7% | 9.3% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $4.72M USD | -48.4% | +9.5% | 53.0% |
| Peer median (excluding ACTU) | — | -37.5% | -11.0% | 9.7% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.